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Abstract
Epstein Barr virus (EBV) infection expands CD8+ T cells specific for lytic antigens to high frequencies during symptomatic
primary infection, and maintains these at significant numbers during persistence. Despite this, the protective function of
these lytic EBV antigen-specific cytotoxic CD8+ T cells remains unclear. Here we demonstrate that lytic EBV replication does
not significantly contribute to virus-induced B cell proliferation in vitro and in vivo in a mouse model with reconstituted
human immune system components (huNSG mice). However, we report a trend to reduction of EBV-induced
lymphoproliferation outside of lymphoid organs upon diminished lytic replication. Moreover, we could demonstrate that
CD8+ T cells against the lytic EBV antigen BMLF1 can eliminate lytically replicating EBV-transformed B cells from
lymphoblastoid cell lines (LCLs) and in vivo, thereby transiently controlling high viremia after adoptive transfer into EBV
infected huNSG mice. These findings suggest a protective function for lytic EBV antigen-specific CD8+ T cells against EBV
infection and against virus-associated tumors in extra-lymphoid organs. These specificities should be explored for EBV-
specific vaccine development.
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Introduction
Epstein Barr virus (EBV) is a ubiquitous human c-herpesvirus
that establishes persistent infection in more than 90% of the
human adult population [1]. Like other herpesviruses, EBV can
undergo two infection programs. Latent infection leads to the
expression of eight viral proteins and more than forty non-
translated RNAs. This program is able to immortalize human B
cells and is found in EBV associated tumors [2]. In contrast, lytic
EBV infection leads to the expression of more than eighty lytic
EBV proteins and the production of infectious viral particles [3].
Human T cells recognize both latent and lytic EBV antigens with
distinct hierarchies [4]. While the latent nuclear antigen 1
(EBNA1) is a consistently recognized CD4+ T cell antigen [5],
latent membrane protein 2 (LMP2) and the EBNA3 proteins are
prominent CD8+ T cell antigens [6]. Furthermore, CD4+ T cells
often recognize late lytic EBV antigens [7], while CD8+ T cells
arise in response to early lytic antigens, including BMLF1 [8].
While EBV transformed B cells (Lymphoblastoid cell lines (LCLs))
can be readily recognized by CD8+ T cells specific for lytic EBV
antigens, the protective value of lytic antigen-specific CD8+ T cells
has not been readily demonstrated so far. Moreover, the expansion
of these lytic EBV antigen-specific CD8+ T cells seems to follow
viral load during symptomatic primary infection, called infectious
mononucleosis, while latent EBV antigen-specific T cells peak
during convalescence consistent with their involvement in viral
immune control [4]. Thus, we aimed to evaluate the protective
role of lytic EBV antigen specific CD8+ T cells in vitro and in vivo.
Due to its exclusive tropism for human cells, this oncogenic c-
herpesvirus is difficult to study in vivo. However, recent advances
have led to the development of two informative in vivo models.
One model examines the infection of rhesus macaques with
lymphocryptoviruses (LCV), a subgroup of c-herpesviruses that
includes EBV [9], and the other model examines EBV infection in
mice with reconstituted human immune system components [10].
In both systems, T cell targeted immunosuppression leads to loss of
viral immune control and virus-associated tumor formation
[11,12,13]. We have explored EBV infection of non-obese diabetic
mice with a severe combined immunodeficiency mutation and
with complete loss of the interleukin 2 receptor gamma chain locus
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(NOD-scid IL2Rcnull or NSG). These mice were reconstituted
with human immune system components (huNSG mice). In this
model, both CD4+ and CD8+ T cells contribute to adaptive
immune control of EBV [13,14]. Furthermore, it allows the
assessment of innate immune responses by natural killer (NK) cells
in response to EBV infection [14,15] and the exploration of EBV-
specific vaccine candidates targeted to dendritic cells [16,17].
Finally, the infection of huNSG mice with EBV isolates and
mutants with enhanced tumorigenesis replicate clinical features of
EBV infection [18,19]. Thus, this in vivo model of EBV infection
recapitulates main features of EBV infection in humans and
should allow us to interrogate the protective value of T cell
responses against latent and lytic EBV antigens.
In this study, we demonstrated that wild-type (WT EBV) and
BZLF1 deficient EBV (ZKO EBV), which lacks with BZLF1 one
of the immediate early transactivators of lytic replication, replicate
to similar viral titers in huNSG mice. However, BZLF1 deficient
virus establishes B cell lymphomas less efficiently outside of
secondary lymphoid tissues. Furthermore, CD8+ T cells specific
for the lytic EBV antigen BMLF1 eliminate lytically EBV
replicating B cells efficiently in LCL cultures in vitro and in
huNSG mice in vivo, thereby transiently controlling EBV
infection in huNSG mice. Thus, lytic EBV antigen-specific
CD8+ T cells are able to target cells infected with lytically
replicating virus. These antigens should be considered for EBV-
specific vaccine formulations, and in particular for patients with
uncontrolled primary lytic EBV replication such as infectious
mononucleosis.
Materials and Methods
Mice
NOD-scid IL2Rcnull HLA-A2 transgenic (NSG-A2tg) mice
were obtained from the Jackson Laboratory, and bred and raised
under specific pathogen-free conditions at the Institute of
Experimental Immunology, University of Zu¨rich, Switzerland.
Newborn NSG-A2tg mice (1 to 5 days old) were irradiated with 1
Gy and injected intrahepatically 5–7 hours later with 1–26105
HLA-A*02 positive CD34+ human hematopoietic progenitor cells.
CD34+ cells were isolated as described previously from human
fetal liver tissue (Advanced Bioscience Resources, Alameda, CA,
USA) [13,18]. The reconstitution of human immune system
components in the peripheral blood of humanized NSG-A2tg
mice (huNSG-A2tg) was analyzed for each cohort 12 weeks after
engraftment and prior to the beginning of experiments.
Ethics statement
All animal protocols were approved by the cantonal veterinary
office of Zurich, Switzerland (protocol nos. 116/2008 and 148/
2011). All studies involving human samples were reviewed and
approved by the ethical committee of Zurich, Switzerland
(protocol no KEK-St-Nr 19/08). These protocols follow the
European Convention for the Protection of Vertebrate Animals
used for Experimental and Other Scientific Purposes as well as the
Swiss Animal Welfare Act (TSchG; 455) (Amendment of 15 June
2012) and the Swiss Animal Welfare Ordinance (TSchV; 455.1).
Virus infection in vitro
Epstein-Barr virus B95-8 wild-type (WT EBV) and BZLF1
knock-out (ZKO EBV) virus were produced in 293 HEK cells
(kindly provided by Regina Feederle and Henri Jacques Delecluse,
Heidelberg, Germany). Titration of viral concentrates was
performed on Raji cells using serial dilution and calculated as
Raji infection units (RIU) using flow cytometric analysis of GFP-
positive Raji cells 2 days after infection. Bulk peripheral blood
mononuclear cells (PBMCs) were isolated from buffy coats by
centrifugation using Ficoll-Paque, stained with carboxyfluorescein
succinimidyl ester (CFSE) and incubated with mock, WT or ZKO
EBV at a multiplicity of infection of 0.01 in the presence of
cyclosporine A (CsA, 1 mg/ml). Cultures were harvested and
counted every 2–3 days. Absolute numbers of cells were counted
using trypan blue exclusion and assessed by flow cytometry. In
order to maintain cultures in the logarithmic growth phase, they
were maintained at a maximal density of 16106 cells/ml and
supplemented with fresh media every 5 days. Assays were
performed on PBMCs from two EBV-seropositive donors in
duplicate.
Infection of mice and adoptive transfer experiments
Fourteen to sixteen weeks after engraftment, huNSG-A2tg mice
were injected with 105 RIU of WT, ZKO EBV or with PBS
intraperitoneally, bled weekly starting from week 2 and euthanized
6 weeks after infection. For adoptive transfer studies, mice received
16106 of LMP2- or BMLF1-specific CD8+ T cell clones
intravenously one day prior to infection, and they were euthanized
4 or 6 weeks post-infection. Clones for adoptive transfer were
selected based on their level of IFNc secretion. All cell transfer
experiments were performed with either of two independently
obtained LMP2- or BMLF1-specific T cell clones. After termina-
tion of the experiments, body and spleen weight were determined.
Abdominal organs were analyzed macroscopically for the presence
of visible tumors.
Immunohistochemistry
Tissue was fixed using 4% formalin and then paraffin
embedded. For immunohistochemistry, anti-CD20 (L26, Cell
Marque Lifescreen), anti-EBNA2 (PE2, Novocastra Laboratories
Ltd), anti-NKp46 (BAF 2225, R&D Systems), anti-human CD68
(514H12, Novocastra Laboratories Ltd), anti-neutrophil elastase
(NE, ab21595, Abcam), anti-gp350 (OT6, kindly provided by Dr.
J.M. Middledorp, VU University Medical Center, The Nether-
lands) or anti-ZEBRA antibodies (AZ-69, Argene) were used and
Author Summary
Epstein Barr virus persistently infects more than 90% of the
human adult population. While fortunately carried as an
asymptomatic chronic infection in most individuals, it
causes B cell lymphomas and carcinomas in some patients.
Symptomatic primary EBV infection, called infectious
mononucleosis, predisposes for some of these malignan-
cies and is characterized by massive expansions of
cytotoxic T cells, which are mostly directed against lytic
EBV antigens that are expressed during virus particle
production. Therefore, we investigated the protective role
of lytic EBV antigen specific T cells during EBV infection
and the contribution of lytic EBV infection to virus-
associated tumor formation. We found that lytic EBV
antigen specific T cells kill B cells with lytic virus replication
and might thereby transiently control EBV infection in
mice with human immune system components. Further-
more, we observed that EBV associated B cell tumors
outside secondary lymphoid organs may require lytic
replication for efficient formation. Thus, we suggest that
lytic EBV antigens should be explored for vaccination
against symptomatic EBV infection and EBV associated
extra-lymphoid tumors.
Protection by Lytic EBV Antigen Specific CD8+ T Cells
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4 mm sections were processed using standard procedures on a
BOND-MAX automated immunohistochemistry system (Leica
Microsystems). Isotype staining served as negative control and
EBV-positive specimen of human tonsil or control or M81-
infected huNSG-A2tg mouse tissue as positive controls. The
absolute number of ZEBRA+ (BZLF1+, BZ.1+) cells per spleen
section was counted in a blinded fashion and normalized to the
total area of spleen section. The total area of spleen sections was
determined using ImageJ Software. The number of CD20+,
EBNA2+, NKp46+, CD68+ and NE+ cells was counted for 5 and
10 fields per spleen at6200 and6400 magnification, respectively.
Quantification of EBV load by real-time PCR
Total DNA from the whole blood was extracted using
NucliSENS (bioMe´rieux) according to manufacturer’s instructions.
Splenic tissue was processed using QIAmp tissue Kit (QIAGEN)
using the manufacturer’s protocol. Quantitative analysis of EBV
DNA was performed by TaqMan (Applied Biosystems) real-time
PCR technique as described [20] with modified primers for the
BamH1 W fragment (59-CTTCTCAGTCCAGCGCGTTT-39
and 59-CAGTGGTCCCCCTCCCTAGA-39) and a fluorogenic
probe (59-(FAM)-CGTAAGCCAGACAGCAGCCAATTGT-
CAG-(TAMRA)-39). All PCRs were run on an ABI Prism 7700
Sequence Detector (Applied Biosystems) and samples were
analyzed in duplicates. No EBV DNA was detected in the blood
of mock-infected animals for the duration of the experiment. Mice
were considered uninfected if EBV DNA was not detected in the
blood and spleen during the experiment.
Flow cytometry
To analyze B cell outgrowth in in vitro assays, cells were labeled
using anti-CD19 (HIB19, Biolegend), anti-CD3 (UCHT1, Biole-
gend), and anti-CD23 (M-L233, BD Biosciences) antibodies. The
composition of blood and spleen samples from humanized mice
was analyzed using anti-human CD45 (HI30, Biolegend), anti-
CD3 (MHCD1918, Invitrogen), anti-CD4 (RPA-T4, Biolegend),
anti-CD8 (SK.1, Biolegend), and anti-CD19 (MHCD1917,
Invitrogen) antibodies. Spleens were mechanically disrupted and
filtered through a 70 mm cell strainer. Erythrocyte lysis in whole
blood or in spleen suspensions was done using NH4Cl. Cell
suspensions were stained with antibodies for 20 min at 4uC and
washed. To sort EBV-specific CD8+ T cells, PBMCs were isolated
using Ficoll-Paque, washed and stained using PE-labeled HLA-
A*0201 dextramers complexed with the following peptides: HIV
gag77–85 (SLYNTVATL), LMP2426–434 (CLGGLLTMV) and
BMLF1259–267 (GLCTLVAML) (Immudex MHC Dextramer).
For staining HLA-A*0201 dextramers loaded with the BRLF1109–
117 (YVLDHLIVV) or with the LMP1159–167 (YLQQNWWTL)
were used in addition. Cells were incubated with dextramers for
10 min at room temperature followed by antibody labeling with
anti-CD3 (UCHT1, Biolegend), and anti-CD8 antibodies. To
assess the purity of the clones, cells were stained using the antibody
combination described in the assessment of the reconstitution
above together with relevant dextramer or irrelevant dextramer as
negative control. To assess the expression of homing and
activation molecules, cells were labeled with anti-CD62L
(DREG56, BD Pharmigen), anti-CCR7 (clone 150503, R&D
Systems), anti-HLA-DR (L243, Biolegend) and anti-CD25 (M-
A251 and 2A3, BD) antibodies. To detect cytotoxic granules in T
cell clones, cells were stained as described, fixed, permeabilized
and stained intracellularly using anti-perforin (dG9, BD Pharmi-
gen) and anti-granzyme B (GB11, BD Pharmigen) with corre-
sponding isotype controls. To detect lytically replicating B cells in
killing assays, cells were labeled with anti-CD19 (HIB19,
Biolegend) and anti-CD3 (MHCD0328, Invitrogen) antibodies,
fixed, permeabilized and stained intracellularly using mouse
anti-ZEBRA (BZ.1, Santa Cruz) primary antibodies (or isotype
control) and secondary goat anti-mouse PE antibodies (BD
Biosciences). Dead cells were excluded based on LIVE/DEAD
fixable Aqua labeling (Invitrogen). Fixation and permeabilization
steps prior to intracellular stainings were performed using BD
Cytofix/Cytoperm Kit. Fluorescently labeled cell suspensions were
analyzed on a BD FACS Canto II or BD LSR Fortessa flow
cytometer (BD Biosciences). Flow cytometric data analysis was
performed using FlowJo software.
Generation of EBV-specific T cell clones
EBV-specific T cells were sorted from the blood of a healthy
HLA-A*0201 positive EBV carrier using LMP2- or BMLF1-
specific dextramers. The donor was genotyped as HLA-A*02,
A*68, B*44, and B*07. Dextramer positive populations live
CD3+CD8+ cells were single-cell sorted and plated onto irradiated
PBMCs and LCLs as feeders in the presence of 1 mg/ml
phytohemagglutinin L (PHA-L) and 150 U/ml hrIL-2 as previ-
ously described [21]. After 2 weeks, T cells were tested in a split
well assay for IFNc secretion upon re-stimulation with 1 mM of
relevant peptides. T cells specifically recognizing the tested peptide
were re-stimulated with the same protocol. They were tested on
day 13 for phenotypic characteristics by flow cytometry and for
functional T cell avidity in peptide titration assays.
Sequencing of TRAV and TRBV gene rearrangements
The TRAV and TRBV chain repertoire was assessed using a
primer set as previously described [22]. Primers were obtained
from Biomers (Ulm, Germany). PCR amplification was performed
in a 25 ml reaction volume containing Pfu polymerase Buffer,
200 mM deoxynucleotide triphosphate, 0.5 mM C3 primer, 0.5 U
Pfu DNA Polymerase (all reagents were provided by Thermo
Fisher Scientific, Reinach, Switzerland), 0.5 mM forward primer,
and 100 ng cDNA. The cycling conditions were as follows: initial
denaturation for 4 min at 95uC and 35 cycles of 95uC for 30 s,
primer annealing at 60uC for 20 s, and primer extension at 72uC
for 60 s, terminated by a final extension at 72uC for 10 min. The
PCR product was validated by electrophoresis in a 2% agarose gel.
Nucleotide sequencing of PCR products was performed at
Microsynth (Balgach, Switzerland) with 30 pmol of reverse C1
primer. TCR gene designations follow the ImMunoGeneTics
(IMGT) nomenclature (http://www.IMGT.org).
T cell clone epitope avidity, MHC-restriction and
degranulation assays
For peptide titration assays, 16104 cells of EBV-specific clones were
incubated with synthetic cognate peptides (Shanghai Biochem) for
18 h. LMP2 peptides and BMLF1 peptides at 5 mM concentration
served as an irrelevant control for BMLF1- and LMP2-specific CD8+
T cell clones, respectively. For co-culture assays, clones were incubated
with HLA-A*02 mismatched or autologous lymphoblastoid cell lines
(LCLs) in an effector to target (E:T) ratio of 1:5. LCLs were optionally
pulsed with 1 mM cognate peptide for 1 h at 37uC and washed
extensively. Supernatants were used for IFNc ELISA (Mabtech). For
degranulation assays, clones were incubated with cognate or control
peptide for 8 h and then stained intracellularly with perforin and
granzyme B antibodies using the BD Cytofix/Cytoperm Kit.
In vitro killing assay
To evaluate the cytotoxic activity of T cell clones against the
autologous LCLs, we performed functional in vitro killing assays.
Protection by Lytic EBV Antigen Specific CD8+ T Cells
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Autologous LCLs were generated by incubating bulk PBMCs from
the T cell clone donor with B95-8 supernatants and used as
targets. AKBM cells, genotyped as A*24, A*31; B*35, B*51; C*09,
and C*14, were used as a mismatched control target. EBV positive
AKBM cells that express GFP upon switching from latent to lytic
EBV replication were induced to enter lytic cycle by ligation with
F(ab9)2 IgG and used directly for co-culture experiments [23].
AKBM or autologous LCLs were incubated with BMLF1- or
LMP2-specific CD8+T cell clones for 18 h at an E:T ratio of 1:1
and stained intracellularly using ZEBRA (BZ.1, Santa Cruz)
antibodies. Specific lysis was determined by using the formula: %
lysis = 1006(12[(experimental ZEBRA+ with effectors 2 mean
isotype ctrl)/(mean ZEBRA+ without effectors 2 mean isotype)].
Negative value for specific killing indicates an increase in number
of ZEBRA+ B cells. Two to four replicates were used for each
condition.
HLA-genotyping
Genomic DNA was isolated from cell type of interest using
Qiagen DNeasy Kit and genotyped by PCR-SSP method using
HLA-A*/-B*/-DRB1* und HLA-DQB1* Kit (Ptotrans).
Statistical analysis
All data were analyzed with the Mann Whitney test, unless
otherwise stated. A p value of ,0.05 was considered statistically
significant. Statistical analysis and the generation of graphs was
performed using Prism software (GraphPad Software).
Accession numbers
The GenBank accession number for the complete B95-8 wild
type sequence is AJ507799.2 (Table S3). The UniProtKB/Swiss-
Prot identification of BMLF1-protein is Q04360. The Uni-
ProtKB/Swiss-Prot identification of LMP2-protein sequence is
P13285. The Immune Epitope Database identification numbers of
HLA-A*02-restricted BMLF1259–267 and LMP2426–434 epitopes
are 20788 and 6568, respectively.
Results
Lytic replication does not significantly contribute to B cell
transformation in vitro
To understand the relevance of lytic infection and EBV lytic
antigen-specific T cell immune responses in the control of EBV
infection and virus-mediated B cell transformation, we used a
recombinant EBV virus devoid of the lytic immediate early
transactivator BZLF1 that is severely compromised to enter the
lytic replication [24]. We first performed in vitro assays to assess if
lytic replication itself has an effect on the initial transformation of
B cells. Bulk peripheral blood mononuclear cells (PBMCs) from
two EBV seropositive donors were infected with either WT or
ZKO EBV with equal multiplicities of infection. This was done in
the presence of cyclosporine A, an immunosuppressive drug that
inhibits T cell responses, so that B cell outgrowth would not be
affected by the presence of endogenous EBV-specific memory T
cells in the assay. Three weeks post-infection, the absolute number
of cells increased in the EBV-containing wells (Figure 1A), as
previously reported for another EBV strain [25]. Flow cytometry
analysis of the infected cells revealed that elevated cell numbers
were due to the outgrowth of EBV transformed B cells (Figure 1B).
Transformed B cells up-regulated expression of the cellular
activation marker CD23 early after infection as compared to the
non-infected control (Figure S1). Both viruses had similar initial
transformation kinetics, which was confirmed by comparable
CFSE dilution in both WT and ZKO EBV transformed B cells
(Figure 1C, Figure S1). Additionally, these transformed cells
revealed similar proliferation rates few months after transforma-
tion as reported previously (data not shown) [26]. Thus, lytic
replication, as demonstrated using ZKO EBV, does not signifi-
cantly contribute to the transformation of B cells and the
subsequent proliferation of EBV-transformed B cell lines, referred
to as lymphoblastoid cell lines (LCLs), in vitro.
Effect of lytic replication on infection and extra-lymphoid
tumorigenesis in vivo
To address whether lytic EBV replication has an effect on in
vivo pathogenesis, we used a mouse model with reconstituted
human immune system components (huNSG-A2tg mice). Three
independent cohorts of humanized NSG-A2tg mice were infected
with WT or ZKO EBV and monitored for 6 weeks after infection
(Figure 2A). Whereas infrequent lytically replicating cells, which
express BZLF1 protein (ZEBRA, BZ.1), were detected in the
spleen sections of the majority of the WT EBV infected animals,
no lytically replicating ZEBRA+ cells were detected in the spleen
sections from ZKO EBV-infected mice (Figure S2). However,
expression of the late lytic EBV antigen gp350 persisted in ZKO
EBV-infected animals, which might indicate a low level of weak
lytic replication in the absence of BZLF1 (Figure S2). EBV DNA
Figure 1. Lytic replication does not significantly contribute to EBV transformation in vitro. Bulk PBMCs were inoculated with WT EBV, ZKO
EBV or mock treated in the presence of cyclosporine A. (A) Cells were harvested and absolute cell numbers per well were determined on indicated
days. (B) Outgrowth of transformed CD19+ B cells was monitored using flow cytometry. (C) Proliferation of EBV transformed B cells was demonstrated
by CFSE dilution and the subsequent increase in percentage of CFSElow B cells. The experiments were performed in duplicate and data is presented as
the mean 6 SEM. Similar results were obtained in samples from two donors; the average of two experiments is presented (p mock vs WT/ZKO ,0.0001
by two-way ANOVA).
doi:10.1371/journal.ppat.1004333.g001
Protection by Lytic EBV Antigen Specific CD8+ T Cells
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was detected in the blood starting at week 2. The EBV virus titer
rose rapidly until week 4 and moderately from week 4 to week 6
post-infection (Figure 2B). The detection of EBV DNA in whole
blood in the first and second week post-infection, however, is
limited by method sensitivity (,83 EBV copies/ml). WT and
ZKO EBV replicated in the blood of infected animals with similar
titers at all the time points, except for week three after infection.
Combined data from seven independent cohorts of animals reveals
a significantly lower viremia in the ZKO EBV infected animals at
that time point (Figure 2B). Notably, while blood viremia in all
animals infected with ZKO EBV rarely exceeded 36103 EBV
copies/ml in the third week post-infection, half of the WT EBV
infected animals reached up to 16104 EBV copies/ml in the blood
(Figure 2B). This transient difference was, however, no longer
observed at later time points. These findings suggest a low
frequency of spontaneous EBV lytic reactivation, which transiently
elevated viral loads in half of the WT EBV-infected humanized
NSG-A2tg mice.
We observed an expansion of the CD8+ T cell compartment in
the blood of infected animals, which is a hallmark of acute EBV-
specific immune responses. Healthy EBV carriers as well as PBS-
treated humanized mice maintain CD4+ cells as a majority of the
CD3+ T cell population, whereas viral infection led to expansion
of a subset of cytotoxic CD8+ T cells and the inversion of the
CD8:CD4 ratio, which was more pronounced in WT animals
compared to ZKO EBV infected animals (Figure 2C). Expanded
T cells may be specific for the antigens expressed during the lytic
phase of the EBV life cycle, which is reduced in ZKO EBV
infected animals. While EBV-specific T cells could be detected by
MHC dextramer staining in the blood of healthy EBV carriers
(Figure 3A), the staining intensity for expanded blood and splenic
CD8+ T cell populations in EBV-infected huNSG-A2tg mice was
low (Figure S3), as previously reported [13,27]. Interestingly,
dextramer staining indicated also lytic EBV antigen specific T cell
populations in the spleen of ZKO EBV infected animals, which
along with the low level of gp350 staining in splenic sections could
indicate a low level of weak lytic EBV replication in the absence of
BZLF1. Despite this, the observed CD8+ T cell expansion suggests
that adaptive cell-mediated responses are mounted against EBV
antigens, similar to what has been observed in primary EBV
infection.
Similar levels of EBV DNA were detected in the spleens of WT
and ZKO EBV infected animals after six weeks of infection, while
spleens of PBS-treated animals were free of EBV DNA
(Figure 2D, data not shown). We also examined mice for the
presence of EBV-associated lesions in the abdominal organs, such
as spleen, liver and kidneys, 6 weeks after infection. As previously
reported, ZKO EBV infection seemed to be less aggressive than
WT EBV infection and leads to fewer lymphomas during six weeks
post infection [28]. However, the composite data from four and six
weeks experiments demonstrated no significant difference in total
number of lymphomas between WT and ZKO EBV infected
mice: 12 out of 24 WT EBV infected (50%) and 8 out of 21 ZKO
EBV infected (38%) animals developed lymphomas in one or more
abdominal organs. At least one macroscopically visible B cell
tumor was observed in the spleen of 58% of WT EBV infected
animals, while ZKO EBV caused splenic tumors in 45% of the
infected animals 6 weeks post-infection. Despite this fairly similar
frequency in tumorigenesis in the spleen, a detailed analysis of
abdominal non-lymphoid organs revealed that ZKO EBV infected
animals showed a trend to reduced numbers of lymphomas in the
liver (p = 0.08, Figure 2E). A single mouse developed a kidney
lymphoma six weeks after WT EBV infection. When combining
four and six weeks experiments from 7 independent experimental
cohorts with 21–24 animals per group the trend for loss of
lymphomagenesis in the liver upon ZKO EBV infection was
confirmed (p = 0.06). Histological analysis of the tumors confirmed
the B cell origin of the lymphoproliferative lesions. This was
concomitant with expression of virus-encoded nuclear antigen
EBNA2, which is essential for the establishment of latent EBV
infection (Figure 2F, Figure S4). Up to 60% of B cells of WT and
ZKO EBV infected animals expressed EBNA2, revealing no
difference between those viruses (Figure S4). Furthermore, the
number of NK cells, macrophages and neutrophils were compa-
rable in the spleens of WT and ZKO EBV infected animals
(Figure S5). Macrophage and less often NK infiltration was a
predominant feature of hepatic B cell lesions in WT EBV infected
animals.
Most of the infected animals had splenomegaly, and this
affected WT EBV infected animals more frequently (Figure 2G).
The absolute number of B cells in the spleens remained
unchanged upon infection with WT or ZKO EBV as compared
to uninfected mice (data not shown). Splenomegaly in WT EBV
infected animals resulted from the expansion of CD3+ T cells,
while the expansion of T cells in the spleen was less pronounced in
animals infected with ZKO EBV (Figure 2H). Despite moderate T
cell expansion in the spleens of ZKO EBV infected animals, the
CD8:CD4 ratio was inverted for most of the infected animals
independent of lytic replication, indicating the enrichment of
cytotoxic CD8+ T cells irrespective of lytic replication (Figure 2I).
These results indicate that lytic EBV replication affects viremia
in the blood only transiently. Despite this, high viral loads lead to
the subsequent expansion of CD8+ T cells. The increased
occurrence of tumors in organs other than the spleen indicates
that lytic replication might contribute to the establishment of
lymphoproliferative disease outside of secondary lymphoid organs
in huNSG-A2tg mice.
Lytic but not latent EBV antigen-specific CD8+ T cells can
eliminate lytically replicating cells
As we have previously reported, depletion of CD8+ T cells leads
to poorly controlled WT EBV infection in the humanized NSG
mouse model [13,14]. In order to assess the role of EBV latent and
lytic protein-specific CD8+ T cells in the control of EBV infection,
we established numerous CD8+ T cell clones specific to represen-
tative immunodominant HLA-A*02 epitopes such as LMP2426–434
(latent) and BMLF1259–267 (lytic) from the blood of an HLA-A*0201
positive healthy EBV carrier (Figure 3A). After two rounds of re-
expansion using the unspecific T cell mitogen phytohemagglutinin
plus interleukin 2 in vitro, the cells were confirmed by dextramer
straining to be pure clonal CD8+ T cell populations. Residual
activation-driven CD8 down-regulation was observed for some
clones early after re-stimulation (Figure 3B). For further character-
ization we sequenced T cell receptor variable genes of obtained
several clones (Table S1). We observed frequent TRBV20-1 usage
by BMLF1-specific CD8+ T cell. Whereas, each of BMLF1-specific
CD8+ T cell clones had a unique CDR3b and CDR3a sequence,
two out of three LMP2-specific clones shared the same CDR3b and
CDR3a sequences, indicating their common clonal origin and
explaining their similar behavior in vitro. We also observed frequent
TRVB5-1 usage by LMP2-specific T cell clones. In peptide titration
assays, the functional avidity for LMP2-specific clones was greater
than for BMLF1-specific clones (13.863.261027 M and
4.462.761026 M, respectively, Figure 3C, Table S2).
To assess if these CD8+ T clones were able to recognize cognate
antigen in the context of MHC class I molecules, we performed
co-culture experiments with autologous or allogenic HLA-A*02
negative EBV-transformed LCLs. BMLF1-specific clones secreted
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limited amounts (less than 260 pg/ml) of IFNc upon co-culture
with autologous WT EBV-transformed LCLs (WT LCLs). In
contrast, no IFNc was detected upon co-culture with control
HLA-A*02 negative WT LCLs (nA2 WT LCLs) or LCLs deficient
in lytic replication (ZKO LCLs) (Figure 3D, upper panels). LMP2-
specific CD8+ T cell clones were capable of recognizing both
autologous LCLs (WT LCLs and ZKO LCLs) expressing
endogenously processed LMP2 protein, indicating sufficient
presentation of LMP2 by cell lines. Interestingly, in two
independent experiments the amount of IFNc secreted by three
LMP2-specific T cell clones in response to autologous ZKO LCLs
accounted for 4962% and 20610% of IFNc secreted towards
WT LCLs (Figure 3D, lower panel). As expected, recognition of
autologous WT LCLs by either BMLF1- or LMP2-specific clones
was improved dramatically when targets were pre-incubated with
cognate but not irrelevant peptide (Figure 3D).
In order to address whether the BMLF1- and LMP2-specific
clones were cytotoxic, we first assessed the presence of the pore-
forming protein perforin and the cell death inducing serine
protease granzyme B by intracellular staining. While incubation
with irrelevant peptide resulted in high levels of perforin and
granzyme B in these clones, stimulation with relevant peptide
decreased the intensity of the staining, indicating the release of
cytotoxic granules upon binding of the TCR with the cognate
antigen (Figure 3E).
To demonstrate that BMLF1-specific CD8+ T cell clones were
able to eliminate autologous lytically EBV replicating LCLs in an
MHC class I restricted manner, we co-cultured BMLF1-specific
clones with autologous LCLs that spontaneously enter lytic
replication (B95-8 EBV strain), or with HLA-mismatched AKBM
cells that require the induction of lytic replication (Akata EBV strain)
at a 1:1 effector:target ratio. After overnight co-culture, the presence
of lytically active LCLs was assessed using intracellular BZLF1
(ZEBRA, Zta, BZ.1) staining. The rate of spontaneous lytic
replication in autologous LCLs was very low and reached a
maximum of 2.3% of total B cells at high-density growth conditions
(Figure 4A), while induced lytically active AKBM cells accounted for
30% of total B cells in culture (data not shown). Several independent
BMLF1-specific CD8+ T clones efficiently eliminated ZEBRA+ cells
from autologous co-cultures (74–90% of ZEBRA+ LCLs), while
unspecific killing of mismatched AKBMs did not exceed 24%
(Figure 4B). As a control, co-cultures of autologous LCLs with
LMP2-specific clones led to increased frequencies of ZEBRA+ cells as
compared to control wells without T cells, which is likely due the
killing of latently infected B cells and the subsequent increase in the
relative number of ZEBRA+ cells (Figure 4C). Thus, BMLF1-specific
CD8+ T cell clones can eliminate LCLs with lytic EBV replication in
vitro and might restrict the horizontal transmission of EBV through
release of newly synthesized viral infectious particles.
BMLF1-specific clones can transiently control EBV
infection in vivo
In order to assess if BMLF1- and LMP2-specific CD8+ T cell
clones were able to ameliorate EBV induced pathogenesis in vivo,
we performed adoptive transfer experiments in huNSG-A2tg
mice. Five independent cohorts of humanized NSG-A2tg mice
were injected intravenously with BMLF1- or LMP2-specific CD8+
T cells in order to mimic endogenous circulating effector T cell
populations, which could for example be induced by vaccination
and indeed the transferred clones carried an effector memory
phenotype after expansion (Figure S6). On the next day, mice
were infected with either WT or ZKO EBV and the development
of lymphoproliferative disease was monitored over 4 or 6 weeks
(Figure 5A, Table S2). Adoptive transfer of a BMLF1-specific
CD8+ T cell clones tended to reduce blood viremia in WT EBV
infected animals 3 weeks post-infection, a time-point when EBV
lytic replication results in elevated blood viremia in humanized
NSG-A2tg mice (Figure 2B and 5B). Furthermore, ZEBRA+ B
cells, containing lytically replicating WT EBV, were diminished in
splenic sections of the majority of WT EBV infected animals upon
transfer of BMLF-1 specific CD8+ T cell clones (Figure 5C). No
ZEBRA+ cells were found in splenic sections from ZKO EBV
infected animals (Figure S2). However, the amelioration of the
EBV viremia in the blood of WT EBV infected animals by
adoptive transfer of BMLF1-specific CD8+ T cell clones varied in
the experimental cohorts of humanized NSG-A2tg mice (Fig-
ure 5D). Taken together, these five adoptive transfer experiments
demonstrated that animals which received BMLF1-specific CD8+
T cells prior to WT EBV infection were less likely to develop high
blood viremia (defined as greater than 36103 EBV/ml) at three
weeks post WT EBV infection: only 3 animals out of 14 (21%)
developed high viremia after BMLF1-specific T cell transfer as
compared to 6 out of 14 (43%) after LMP2-specific T cell transfer
or 7 out of 16 (44%) animals in the non-treated group (Figure 5E).
Adoptive transfer of LMP2-specific T cells did not seem to have an
ameliorating effect in WT EBV infected animals, however ZKO
EBV infected animals might have benefitted from the T cell
infusion on the third and fourth week after infection, possibly due
to elimination of latently infected B cells from blood circulation.
Adoptive transfer of partially mismatched T cells in humans is
considered relatively safe [29], despite rare cases of mild graft-
versus-host disease [30]. Humanized mice, which received partly
matched cytotoxic T cell clones, had no signs of graft-versus-host
disease during the experiment. We attempted to identify the
Figure 2. Lytic replication transiently influences viremia and may account to extra-lymphoid tumorigenesis in humanized mice. (A)
Schematic diagram of in vivo infection experiments. Three cohorts of huNSG-A2tg mice were infected intraperitoneally (i.p.) with WT EBV, ZKO EBV or
PBS, bled weekly starting from week 2 post-infection and euthanized at week 6. (B) Whole blood viral load at the indicated time points and presented
as the mean 6 SEM. Data for the initial four weeks represent composite data from 7 independent experimental cohorts of animals (n = 21–24 per
group), data for the fifth and sixth represent composite data from 3 cohorts (n = 11–12 per group) (n.s. p WT vs ZKO = 0.23 by two-way ANOVA;
p week 3: WT vs ZKO,0.05 unpaired t test with Welch’s correction). Dotted line represents detection limit. (C) Peripheral blood composition was analyzed
using flow cytometry and the inversion of CD8-CD4 ratio was assessed weekly during the course of infection. Data is presented as the mean6 SEM (p
WT vs ZKO ,0.001 by two-way ANOVA). (D) EBV DNA load was determined in spleen biopsies and presented as the geometric mean (n.s. p = 0.4 by
unpaired t test). (E) Lymphoproliferative lesions of B cell origin were found in the organs of the abdominal cavity of some infected animals (spleen,
liver and kidneys). Tumor burden is shown as percentage of tumor-bearing animals per group (n.s. p WT vs ZKO = 0.09 by two-way ANOVA, n.s.
p liver:WT vs ZKO = 0.08 and p kidney:WT vs ZKO = 0.16 by one-way Chi-square). (F) Immunohistochemical analysis of tumor sections confirmed the EBV-
associated B cell origin of tumors by CD20 (left panel) and EBNA2 (right panel) staining. Scale bars, 200 mm. (G) Splenomegaly was assessed by
comparing spleen weight to body weight. Data represents the mean 6 SEM (p,0.05). (H) The absolute number of CD3+ T cells in the spleen was
determined at the termination time point and represented as the mean 6 SEM (p PBS vs WT ,0.05, n.s. p PBS vs ZKO = 0.06, n.s. p WT vs ZKO = 0.69). (I) The
inversion of CD8:CD4 ratio in the spleen was determined by flow cytometry and represented as the mean6 SEM (n.s. p WT vs ZKO = 0.98, p PBS vs WT, PBS
vs ZKO ,0.05). Figures C–E represent composite data from three independent experiments with a total of 26 animals. Figure B represents composite
data from seven independent experiments with a total of 45 animals.
doi:10.1371/journal.ppat.1004333.g002
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defining characteristics for protective EBV specific T cell clones by
examining peptide epitope avidity, functional potency and surface
phenotype, but we were unable to identify any in vitro predictors
for in vivo protection. Additionally, attempts to find the
transferred cells by specific amplification of mismatched MHC
class I alleles of the donor using DNA from the blood at weeks 2, 3
and 4 post-infection, as well as in spleens and tumor samples upon
termination of the experiments were limited by the sensitivity of
our PCR-based method (1% of CD8+ T cells) and did not detect
persistence of the transferred clonal T cell populations (data not
shown).
We also assessed the effect of adoptively transferring lytic and
latent antigen specific T cell clones on the formation of
lymphoproliferative disease induced by WT and ZKO EBV.
Consistent with our earlier experiments, EBV infected animals
developed splenic EBV-associated B cell lymphomas with
Figure 4. CD8+ BMLF1-specific clones eliminate lytically replicating EBV transformed B cells in vitro. Selected BMLF1-CD8+ T cell clones
were co-cultured with lytically replicating EBV transformed B cells as targets overnight at an E:T ratio of 1:1. (A) The percentage of lytically active LCLs
was determined using intracellular ZEBRA staining by flow cytometry. Representative FACS plots demonstrate the isotype control background (top),
population of steady state autologous ZEBRA+ LCLs when cultured alone (middle) and population of autologous ZEBRA+ LCLs remaining after co-
culture with BMLF1-specific clonal CD8+ T cells (bottom). Percentages of ZEBRA+ cells were determined within CD19+ B cell populations pre-gated
on live CD3neg cells. (B) Specific lysis of autologous ZEBRA+ LCLs compared to lysis of mismatched ZEBRA+ AKBM is summarized for two independent
experiments. A minimum of two biological and technical replicates were used for each of the experiments (p LCL alone vs E:T 1:1,0.05, p AKBM vs autoLCL,
0.005 by two-way ANOVA). (C) Specific lysis of autologous ZEBRA+ LCLs by BMLF1-specific clones compared to lysis by LMP2-specific CD8+ T cell
clones is summarized for three independent experiments. The experiments were performed with two biological replicates and at least two technical
replicates (p LCL alone vs E:T 1:1, BMLF1-T vs LMP2-T ,0.001 by two-way ANOVA).
doi:10.1371/journal.ppat.1004333.g004
Figure 3. CD8+ T cell clones of lytic (BMLF1) and latent (LMP2) specificity were established by single cell sorting. (A) A dextramer
positive population of live CD3+/CD8+ cells was sorted by flow cytometry from the blood of an HLA-A*0201 positive healthy EBV carrier. Flow
cytometry plots show the frequency of starting populations within CD8+ T cells. (B) After two rounds of PHA re-expansions of sorted single cells, the
purity of the T cell clones was confirmed by staining for T cell receptor specificity (MHC-dextramers), CD3, CD4, and CD8. Representative dextramer
staining plots for three clones of LMP2-specificity (dark grey) and three clones of BMLF1-specificity (black) are shown, together with an overlay of
control staining with an irrelevant dextramer (light grey). (C) Epitope avidity was determined in peptide titration assays for BMLF1-specifc clones
(top) and LMP2-specific clones (bottom). The presence of IFNc in supernatants upon stimulation with various concentrations of cognate peptide
was assessed by ELISA and is presented as the mean 6 SEM. Assays were performed in duplicate. (D) The ability to recognize HLA-A*02 negative WT
LCLs, autologous WT LCLs and ZKO LCLs as well as peptide-pulsed WT LCLs was assessed for BMLF1-specific clones (top panels) and LMP2-specific
clones (bottom panel) by IFNc ELISA of supernatants after co-culture (n.d. – not detected). (E) FACS histograms of intracellular perforin and
granzyme B staining for selected clones after stimulation with LMP2 (grey) and BMLF1 (black) peptides. An isotype control for intracellular staining
is represented as a shaded grey histogram.
doi:10.1371/journal.ppat.1004333.g003
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comparable frequency irrespective of lytic replication, whereas
extra-lymphoid lymphomas were less frequent when EBV lytic
replication was impaired (Figure 5F). Lymphomas from both WT
and ZKO EBV infected animals contained EBNA2+ B cells,
indicating the latency III program of the EBV life cycle. This form
of latency is characterized by expression of all latent EBV antigens,
namely EBNA proteins 1, 2, 3A, B, C, -LP, and LMP proteins 1
and 2. Latency III is commonly found in the lymphoproliferative
lesions of immune-compromised patients.
Our study demonstrates subtle effects of EBV lytic replication
on blood viremia and suggests that endogenous EBV lytic antigen-
specific T cells might be primed in the huNSG-A2tg mice.
Furthermore, we observed that EBV lytic replication may be
required for the establishment of extra-lymphoid lymphoprolifer-
ative lesions in our mouse model. In healthy EBV carriers,
memory CD8+ T cell specific for lytic and latent antigens of EBV
are found in significant numbers. In this study, we provide the first
evidence that BMLF1-specific CD8+ T cells eliminate EBV-
transformed B cells undergoing lytic replication in vitro and in
vivo, and are able to transiently control EBV viremia in the blood
of infected humanized mice.
Discussion
One form of uncontrolled lytic EBV replication is infectious
mononucleosis. This symptomatic primary EBV infection occurs
more frequently when primary viral infection is delayed into
adolescence. It is characterized by high viral titers, particularly in
saliva, and by CD8+ T cell lymphocytosis [31]. Otherwise,
pathology by lytic replication of EBV is rare in healthy human
carriers and EBV transformed lymphoblastoid cell lines switch
only at low frequencies into lytic replication in vitro. Despite these
findings, the role of lytic virus replication during EBV infection is
only poorly understood. This is in part because the number of
experimental systems that are permissive for EBV infection limits
studies on EBV biology in vivo. We therefore examined EBV lytic
replication in humanized NSG-A2tg mice and the functional role
of BMLF1-specific T cells in the control of EBV infection in vivo
and in vitro. This in vivo model of EBV infection recapitulates
hallmarks of innate and adaptive cell-mediated immune control of
EBV, but lacks the development of humoral immune responses
and efficient mucosal homing of human immune cells [10].
Our longitudinal in vivo study suggests that EBV lytic
replication is limited in our humanized mouse model and plays
a transient role in dissemination of the EBV early after infection
and prior to innate and adaptive immune control of lytically EBV
replicating cells: only mice infected with lytic replication compe-
tent EBV, but not lytic replication compromised EBV, developed
high viremia in the blood on the third week post-infection.
The massively expanding CD8+ T cells in infectious mononu-
cleosis patients are mostly directed against lytic EBV antigens [32],
suggesting that primarily lytic viral replication is ill-controlled
during infectious mononucleosis. Particularly, CD8+ T cells that
are specific for immediate early and early EBV antigens are
observed at high frequencies [33]. These events correlate with
more efficient LCL recognition by early lytic EBV antigen specific
CD8+ T cells, while late lytic EBV antigen recognition by specific
CD8+ T cells is presumably compromised by viral immunoevasins
targeting MHC class I antigen presentation [34]. In our
humanized mouse model we observed that high blood viral load
frequently correlated with the number of EBV-specific T cells
found in the spleens of the WT and ZKO EBV infected animals as
detected by IFNc ELISPOT assays (data not shown). Also, we
report the inversion of the CD8:CD4 ratio in blood of infected
animals, which is less pronounced in animals infected with EBV
that is inhibited in its lytic replication. Our lab previously
demonstrated that a significant proportion of EBV-specific T cells
are primed specifically to lytic antigens rather than latent antigens
in humanized NSG-A2tg mice [13]. These data suggest that
lytic EBV antigens contribute to CD8+ T cell expansion after
infection.
However, in our current study, we observe more EBV-specific
T cells among splenocytes from both WT and ZKO EBV infected
mice, if we stimulated the splenocytes with LCLs capable of lytic
EBV replication (data not shown). Together with the observation
in vitro that LMP2-specific CD8+ T cell clones consistently
secreted more IFNc in response to autologous WT LCL than to
ZKO LCL stimulation, this might indicate decreased antigen
presentation of LCLs deficient in lytic replication. Additionally,
detection of EBV-specific T cells using HLA-A*02 dextramers
bound to human immunodominant epitopes of EBV lytic and
latent proteins was difficult due to low staining intensity (Figure
S3). The process of T cell education of the T cells in humanized
mice remains unclear. In these mice human T cells are educated
on mouse thymic epithelial cells, human bone marrow derived
cells or transgenic human MHC class I molecules stabilized by
murine b2-microglobulin. We can speculate that this may result in
T cells with TCRs, that are suboptimally recognized by human
HLA-A*02 dextramers. Alternatively, maintenance of high TCR
density on T cells in the mouse host might be compromised by lack
of human cytokines and further compromised due to the high
antigenic load after EBV infection.
Pudney and colleagues demonstrated direct recognition of
lytically infected cells by CD8+ specific cells obtained from
infectious mononucleosis patients [34]. However, in these studies,
the authors could only demonstrate cytokine production by lytic
EBV antigen specific CD8+ T cell clones in response to wild-type,
but not BZLF1-deficient LCLs. Extending these findings, we can
now document that BMLF1 specific CD8+ T cell clones eliminate
ZEBRA expressing EBV infected B cells in LCL cultures. BMLF1-
specific clones eliminated EBV lytically replicating autologous
LCLs, but not MHC-class I mismatched control LCLs. Thus, lytic
EBV antigen specific T cell clones contribute to the immune
Figure 5. Lytic EBV antigen specific CD8+ T cell clones can transiently control EBV infection in humanized mice. (A) Schematic diagram
of adoptive transfer experiments. BMLF1- or LMP2-specific CD8+ T cell clones were transferred i.v. into humanized NSG-A2tg mice. The next day, mice
were infected i.p. with WT EBV, ZKO EBV or PBS. Mice were bled weekly starting at week 2 post-infection and were euthanized at week 4 or 6 post-
infection (n = 94). (B) Whole blood EBV loads for the second, third and fourth week post-infection of mice, which received BMLF1- or LMP2-specific
CD8+ T cell clones prior to WT or ZKO EBV infection, is demonstrated for a representative experiment (cohort 2, n = 3–4 per group, total n = 21).
Dotted line represents detection limit. (C) Representative figures and quantification of the ZEBRA+ cells in the spleen sections of WT EBV infected
huNSG-A2tg mice, which received no T cells, BMLF1-specific T cell clones and LMP2-specific T cell clones for two initial experiments (n = 6–7 per
group, total n = 20). Data represent the mean 6 SEM (p no T vs BMLF1-T ,0.01, p BMLF1-T vs LMP2-T = 0.07). Scale bars, 100 mm. (D) Whole blood EBV loads
for the second, third and fourth week post-infection of mice from five independent adoptive transfer experiments (n = 94). Data are represented as
the mean6 SEM. (E) Incidence of high blood viremia on the third week post-infection in the WT EBV infected mice, which received no T cells, BMLF1-
specific T cell clone and LMP2-specific T cell clone (n.s. by one-way Chi-square). (F) Tumor incidence per organ is presented as the percentage of
animals which developed visible tumors in the organs of the abdominal cavity (n = 92).
doi:10.1371/journal.ppat.1004333.g005
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control of EBV infection by eliminating lytically virus replicating
cells.
Another EBV-associated pathological condition in solid-organ
and hematopoietic stem cell transplant patients is post-transplant
lymphoproliferative disease (PTLD). This disease almost exclu-
sively involves EBV-associated B cell proliferations characterized
by expression of all latent proteins of EBV (latency III). In
immune-compromised PTLD patients, mostly polyclonal B cell
lesions could be found in secondary lymphoid organs and extra-
lymphoid tissues [2]. EBV infection of humanized mice leads to
the formation of lymphoproliferative B cell lesions resembling
PTLD in histology and expression pattern of viral proteins.
EBER+ EBV-transformed B cells were found in similar multifocal
sites independently of lytic replication in humanized NSG mice,
which were implanted with human fetal thymus and liver
fragments in addition to the fetal liver derived CD34+ stem cell
transfer of our model [28]. Our study for the first time
demonstrates that EBV may require lytic replication to efficiently
establish lymphomas in non-lymphoid tissues like kidneys and
liver. This could result from decreased expression of growth factors
in ZKO-derived LCLs, which may be more critical for the
establishment of lymphoproliferative lesions outside of secondary
lymphoid organs [26].
One therapy for patients with PTLD is adoptive T cell transfer.
Both CD8+ and CD4+ EBV-specific T cells are being explored for
adoptive transfer into PTLD patients [35,36,37,38,39]. Here we
report, that adoptive transfer of BMLF1-specific CD8+ T cell
clones into WT EBV infected humanized NSG mice transiently
controlled EBV infection and was able to eliminate BZLF1
expressing cells from huNSG-A2tg spleens. However, given the
limitation of detecting lytically replicating cells indirectly by
examining blood viremia, this transfer did not result in significant
and reproducible long-term control of EBV infection. We
addressed whether fluctuations in the control of lytic replication
in vivo was due to the characteristics of the transferred clones
(epitope avidity, phenotype etc). However, no clear correlations
could be found (Table S2). Alternatively, the inefficiency of clonal
T cell transfer may result from the overall HLA mismatch – except
matched HLA-A2 expression – between reconstituted human
immune system components and transferred T cell clones. This
might have led to their alloreactive rejection by the host and the
limited persistence of the transferred cells in vivo. Clinical studies
suggest that a positive outcome of cytotoxic T cell transfer into
PTLD patients positively correlates with the matching of donor T
cells to the recipient [38]. Despite this, an ameliorating effect of
adoptive transfer in PTLD patients could also be observed in
partly matched settings [30,39]. Within five cohorts of huNSG-
A2tg mice reconstituted with one (Cohorts 2, 3) or more (Cohorts
1, 4, 5) matched HLA alleles, the most pronounced effect of
BMLF1-specific clone on viremia in blood was observed
irrespective of the number of matched MHC class I alleles
(Cohorts 1 and 2 at week 3, cohort 3 at week 4). Likewise, adoptive
transfer of partly matched T cell clones in primates revealed no
correlation between persistence of the infused cells and genetic
backgrounds of donor and recipient [40]. Taken into account that
WT EBV infection caused high viremia in half of the infected
humanized NSG-A2tg mice, our study indicates that BMLF1-
specific CD8+ T cells seem to maintain some immune control and
can eliminate B cells undergoing lytic replication. Our data
provide a rationale for reconsidering lytic EBV antigens for EBV
specific vaccination, particularly during uncontrolled lytic replica-
tion and to limit EBV associated tumorigenesis in non-lymphoid
tissues, which seems to be supported by lytic replication per se.
Accordingly, lytic EBV antigens should be explored as vaccine
components to mitigate infectious mononucleosis.
Currently, several EBV specific vaccine candidates are being
explored. These include recombinant gp350 protein formulations
that aim to elicit neutralizing antibodies against the main
attachment protein for complement receptor 1 and 2 (CD35 and
CD21) dependent B cell infection by EBV [41,42,43]. Further-
more, recombinant viral vaccines encoding latent EBV antigens,
for example modified vaccinia virus Ankara (MVA), encoding a
EBNA1-LMP2 fusion protein, are being explored [44,45]. EBV
derived virus like particles devoid of viral DNA have been
investigated as vaccine candidates [46,47,48,49]. Finally, we have
been characterizing EBNA1 targeting to dendritic cells as a
vaccine formulation [16,17,50]. However, all of these vaccination
schemes include either latent or late lytic EBV antigens. They do
not provide any stimulation for the immediate early and early lytic
EBV antigen specific CD8+ T cells, which constitute the most
frequent EBV specificities in both symptomatic primary infection
and healthy EBV carriers. Since these specificities, nevertheless,
efficiently recognize and eliminate lytically EBV replicating B
cells ([34] and our data), they should be included into
vaccine formulations against infectious mononucleosis and possi-
bly also against EBV associated malignancies in extra-lymphoid
tissues.
Supporting Information
Figure S1 ZKO EBV deficient in lytic replication leads
to up-regulation of B cell activation marker CD23 and
subsequent proliferation. Bulk PBMCs were inoculated with
WT EBV, ZKO EBV or mock treated in the presence of
cyclosporine A. Representative FACS plots of mock-treated, WT
EBV and ZKO EBV infected PBMCs on the day 3, 5, and 7 after
infection and pre-gated on CD19+ B cell populations of live
CD3neg cells. The experiment was done in duplicates. Similar
results were obtained for two donors.
(TIF)
Figure S2 ZEBRA+ and gp350 cells in the spleen sections
derived from WT and ZKO EBV infected animals six
weeks post-infection. Spleen sections were screened for
presence of ZERBA+ (upper row) or gp350+ (lower row) cells at
6400 magnification and the total spleen area was defined at640
magnification. Data is composed of three independent experiments
and represent mean6 SEM. p,0.01 by Wilcoxon signed rank test.
(TIF)
Figure S3 Detection of EBV-specific CD8+ T cells in
humanized NSG-A2tg mice six weeks after infection with
WT and ZKO EBV. Representative flow cytometry plots
demonstrating staining of peripheral blood mononuclear cells (A)
and splenocytes (B) using HLA-A*02 dextramers complexed with
lytic (BMLF1, BRLF1), latent (LMP1, LMP2) EBV and control
HIV gag antigen derived peptides. Pre-gated on the population of
live human CD45+ CD3+ lymphocytes.
(PDF)
Figure S4 Quantification of EBNA2-expressing B cells in
spleen sections derived from WT and ZKO EBV infected
animals six weeks post-infection. (A) EBNA2-expressing
cells were quantified in splenic sections for three independent
experiments (n.s. p = 0.42). (B) Percentage of EBNA2-expressing B
cells for WT and ZKO EBV infected animals in spleen sections
was normalized to B cell numbers for three independent
experiments (n.s. p = 0.28). Data represent mean 6 SEM.
(TIF)
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Figure S5 NK and myeloid cell composition in the
spleens and livers of WT and ZKO infected mice 6
weeks after infection. (A) Quantification of cells expressing
NKp46 (n.s. p WT vs ZKO=0.44), human CD68 (n.s. p WT vs ZKO=
0.13) and neutrophil elastase (n.s. p WT vs ZKO=0.72) in the spleen
sections from WT and ZKO EBV infected mice. (B) Quantification
of cells expressing NKp46 (n.s. p WT:control vs tumor=0.25), human
CD68 (p WT:control vs tumor,0.05) and neutrophil elastase (n.s.
p WT:control vs tumor=0.11) in the hepatic tumors and control liver
tissue inWT and ZKOEBV infected mice. (C) Percentages of CD3neg
CD4neg CD19neg lymphocytes (n.s. p=0.90) and CD3neg CD8neg
CD19neg (n.s. p=0.48) leucocytes, but not lymphocytes within human
CD45+ cell population in the spleens of WT and ZKO EBV infected
huNSG-A2tg mice. Data represent composite data from three
independent experiments as mean 6 SEM.
(PDF)
Figure S6 Expression of activation and homing markers
by LMP2- and BMLF1-specific CD8+ T cell clones. Flow
cytometry plots demonstrate activation and homing markers for an
isotype control and two pairs of BMLF1-specific and LMP2-
specific CD8+ T cell clones used for adoptive transfer into
humanized mice. Pre-gated on the population of live human
CD45+ CD3+ CD8+ cells.
(TIF)
Table S1 T cell receptor variable gene usage by LMP2-
and BMLF1-specific CD8+ T cell clones.
(DOCX)
Table S2 Overview of adoptive transfer experiments.
(DOCX)
Table S3 The identification numbers of EBV complete
wild type genome (strain B95.8), proteins and HLA-
A*02-restricted epitopes used in the study.
(DOCX)
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